LOUISVILLE, Kentucky—BrightSpring Health Services, Inc., a provider of home and community-based health services for complex populations, announced financial results for the second quarter of 2026, and increased full year 2026 revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance.
Second Quarter 2026 Financial Highlights:
- Net revenue of $3,873 million, up 23% compared to $3,148 million in the second quarter of 2025
- Gross profit of $493 million, up 31.5% compared to $375 million in the second quarter of 2025
- Net income of $87 million compared to $9 million in the second quarter of 2025
- Adjusted EBITDA1 of $206 million, up 44.2% compared to $143 million in the second quarter of 2025
- Leverage of 2.15x as of June 30, 2026, compared to leverage of 2.27x on March 31, 2026
- $300 M paydown and concurrent modification of the first lien facility, including interest rate refinancings that resulted in interest savings
- Completion of an underwritten secondary offering of common stock by affiliates of Kohlberg Kravis Roberts & Co. L.P. and certain members of management in June 2026, and a concurrent $60.0 million repurchase of 1,026,465 shares of common stock from the underwriter
"We are pleased with the company’s second quarter results that reflect our quality focus, service level performance and dedication to the patients we serve," said Jon Rousseau, chairman, president and CEO of BrightSpring. "We remain grounded in disciplined operational execution and delivering high-quality and effective care. Our service lines have significant long-term opportunity to better address the needs of all healthcare stakeholders, and we remain committed to innovation and leadership in our industry to impact more patients in the future."
For the full year 2026, BrightSpring is increasing revenue and adjusted EBITDA guidance, which excludes the community living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2025 revenue and adjusted EBITDA results, excluding the community living business:
- Revenues of $15,100 million to $15,425 million, or 17.0% to 19.5% growth
- Pharmacy segment revenue of $13,200 million to $13,500 million, or 15.3% to 17.9% growth
- Provider segment revenue of $1,900 million to $1,925 million, or 29.7% to 31.4% growth
- Total Adjusted EBITDA of $820 million to $845 million, or 32.8% to 36.8% growth
- The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026
A reconciliation of the foregoing guidance for the non-generally accepted accounting principles (GAAP) metric of Adjusted EBITDA to GAAP net income from continuing operations cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control or cannot be reasonably predicted. For the same reasons, the company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.